Kornimate/medical-research-clean huggingface dataset:
near-infrared light-emitting diode (nir-led) therapy for leber's hereditary optic neuropathy (lhon)

Conditions: Leber's Hereditary Optic Neuropathy (LHON)

Summary: the overall objective of the proposed research is to test the hypothesis that near-infrared light-emitting diode (nir-led) therapy will stimulate mitochondrial function, attenuate oxidative stress, and improve cell survival and vision in subjects with leber's hereditary optic neuropathy (lhon).

to determine the effects of short term (3 month) near-infrared light nir-led therapy on anatomic and functional abnormalities of lhon as assessed by a wide variety of ophthalmologic tests, including visual acuity, optical coherence tomography, pattern electroretinography (perg) n95 retinal ganglion cell peak, ferg-phnr (flash erg - photopic negative response), and fundus photography.

Eligibility criteria:
inclusion criteria: * sex - male and female. men are affected with visual loss more frequently than women, with a male predominance of \~85%. a minimum of 25% of men and 5% of women at risk for lhon experience visual loss. * age - 18 years or older. the onset of visual loss typically occurs between the ages of 15 and 35 years, but otherwise classic lhon has been reported in many individuals both younger and older, with a range of age at onset from 2 to 80 years. * diagnosis of lhon or a carrier of the gene mutation. patient must be evaluated by molecular confirmation, with the 11778 and other mutations of leber's hereditary optic neuropathy stratified in later data analysis. * able \& willing to provide informed consent exclusion criteria: * has an optic nerve disease other than lhon. * significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant. * participation in an investigational trial within 30 days of nir-led treatment that involved treatment with any drug that has not received regulatory approval at the time of study entry. (note: subjects cannot receive another investigational drug while participating in the study during the first 6 months.) * major surgery within 28 days prior to participation or major surgery planned during the next 6 months. major surgery is defined as a surgical procedure that is more extensive than fine needle biopsy/aspiration, placement of a central venous access device, removal/biopsy of a skin lesion, or placement of a peripheral venous catheter.
cervical cancer screening trial by randomization of hpv testing intervention for upcoming screening （citrus study）

Conditions: Cervical Cancer

Summary: the aim of this study is to assess efficacy of the screening with concurrent liquid-based cytology and hpv dna testing for the primary cervical cancer screening over 7 years.


Eligibility criteria:
inclusion criteria: 1. women aged 30-64 years old 2. participants provided written informed consent exclusion criteria: women who 1. will receive planed hpv dna testing by local governmental cervical cancer program next six years 2. have had cervical invasive cancer before 3. have undergone cervical conization 4. have undergone hysterectomy 5. have had or have the cytological abnormalities and are under follow-up 6. are pregnant 7. are judged ineligible for this trial by physician
behavioral nudges for diabetes prevention (begin) trial in primary care

Conditions: PreDiabetes

Summary: a large body of research has demonstrated that intensive lifestyle interventions and metformin are effective treatments to prevent or delay diabetes among high-risk adults, yet neither treatment is routinely used in practice. the behavioral nudges for diabetes prevention (begin) trial will test two low-touch interventions designed to motivate adoption of these treatments to prevent diabetes. given that 38% of u.s. adults have prediabetes, the proposed study has potential for large public health impact by testing pragmatic, scalable, and sustainable approaches based in primary care to promote evidence-based treatment for this common condition.

large randomized trials have found that intensive lifestyle interventions (ili) and metformin are safe and effective treatment options for promoting modest weight loss and preventing type 2 diabetes (t2d) among adults with prediabetes. however, these treatments are rarely used in practice, and little existing research has focused on patient-centered approaches for promoting their use. one potential approach, behavioral nudges, involves manipulating health messages and treatment options to make behavior change more likely and easier to enact. while a large body of evidence suggests that behavioral nudges are effective, they have not been definitively studied for t2d prevention. the study team will address this critical knowledge gap by conducting the behavioral nudges for diabetes prevention (begin) trial. the proposed study will take place in primary care clinics, whose unprecedented reach and regular interaction with prediabetic adults make this an ideal setting for translational t2d prevention research. this definitive study will test two low-touch interventions: 1) prediabetes decision aid intervention consisting of a prediabetes decision aid designed to nudge uptake of evidence-based treatments and delivered by health educators; and 2) text messaging intervention consisting of text messages that deliver similar information and use the same behavioral nudges. the proposed r18 study will accomplish the following specific aims to determine the most effective low-touch intervention that promotes maximal treatment adoption and weight loss.

Eligibility criteria:
inclusion criteria: * adult patients (aged 18-80 years) * with prediabetes * overweight/obesity (bmi ≥25kg/m2) * patients who speak english or spanish exclusion criteria: * type 2 diabetes * dementia * serum creatinine \>1.4mg/dl in women and \>1.5mg/dl in men * current use of oral corticosteroids * current pregnancy * uncontrolled hypertension (≥180/100mmhg) * history of metformin use * no office visits during the last 12 months
a study of the use of the q aspiration catheter to remove clot in stroke patients

Conditions: Stroke, Ischemic

Summary: the purpose of this study is to collect real-world safety and performance data on the mivi neuroscience, inc. q aspiration catheter for use in the removal of fresh, soft emboli and thrombi in the neurovascular system during acute ischemic stroke.

the purpose of this study is to demonstrate the safety and performance of the mivi neuroscience, inc. ce marked q aspiration catheter for use in the removal of fresh, soft emboli and thrombi in the neurovascular system during acute ischemic stroke. the study is an observational study collecting q aspiration catheter use that will enroll a maximum of 50 subjects at a maximum of 5 sites in spain. subjects data will be collected through hospitalization with a 3 months post-procedure study visit. this study is designed for observational data to be collected and reported.

Eligibility criteria:
inclusion criteria: * age 18 to 85 years; * diagnosis of acute ischemic stroke with mechanical thrombectomy procedure \< 8 hours from onset of symptoms/ last known well; * large vessel occlusion on ct or mri in the anterior cerebral vasculature up to a1, m1, or m2 or the posterior cerebral vasculature; * aspects 6 - 10 or volume of diffusion restriction \< 50 ml; * use of the q aspiration catheter as the first line treatment according to the ifu; * signed informed consent by patient or legally authorized representative. exclusion criteria: * occlusions in multiple vascular territories, extracranial occlusion or tandem occlusion; * evidence of dissection in the carotid or target artery for treatment; * evidence of recent/fresh haemorrhage on presentation; * unwilling to agree to a 3-month follow up visit.

Keywords: mechanical thrombectomy acute ischemic stroke neurovascular intervention
growth hormone treatment in children born small for gestational age (sga)

Conditions: Foetal Growth Problem; Small for Gestational Age

Summary: this study is conducted in japan. the aim of this trial is to assess the efficacy and safety of somatropin in children born small for gestational age (sga) in japan. in the main period, subjects will receive either active treatment for 104 weeks (two dosing regimens) or no treatment for 52 weeks followed by an extension period where subjects who received active treatment for 104 weeks (two years) will continue with the same treatment for further 156 weeks (three years) while those subjects who received no treatment for 52 weeks (one year) will be randomised to receive two dosing regimens for 208 weeks (four years). in total, subjects participate in trial for 260 weeks (five years). main period is registered internally at novo nordisk as ghliquid-1516 while the extension period is registered as ghliquid-1517.


Eligibility criteria:
inclusion criteria: * for main period (ghliquid-1516): * born small for gestational age (sga) with birth weight and birth length below the 10th percentile for gestational age, and additional either birth length below or equal to -2.0 standard deviation score (sds) or birth weight below or equal to -2.0 sds for gestational age * growth failure with height at -2.0 sds or below for chronological age (ca) * normal growth hormone (gh) production, defined as peak gh level \> 10 ng/ml in one gh provocation test * for extension period (ghliquid-1517): * subjects who completed the main period * chronological age (ca) for boys at least 4 years, but maximum 11 years * chronological age (ca) for girls at least 4 years, but maximum 10 years exclusion criteria: * subjects with diabetes mellitus * subjects suffering from malignancy * several medical conditions
comparison of floseal® and tranexamic acid on bleeding control after total knee arthroplasty

Conditions: Knee Osteoarthritis

Summary: the total knee arthroplasty (tka) is a well established option for the treatment of osteoarthritis in this joint. nevertheless, there are still some concerns related to the peri-operative management of elderly patients, highlighting the complications related to medical comorbidity and bleeding produced by surgery. one of the proposed methods to decrease postoperative bleeding, which has been accumulating favorable evidence, is the use of tranexamic acid (ta). several studies (including prospective randomized trials with placebo group) showed excellent results with ta intravenous administration during tka, reducing the amount of bleeding, the drop in hemoglobin and the need for blood transfusion. another alternative to minimize bleeding is the use of topical hemostatic agent floseal®, composed of thrombin and bovine gelatin. this substance has presented significant benefits on bleeding control in several areas of medicine, including orthopedic surgery, but no action has yet been established in tka. the main objective is to evaluate the amount of bleeding, the drop in hemoglobin and the need for blood transfusion after tka, comparing the use of ta, floseal® and a control group. the secondary objective is to evaluate the rate of adverse events in the studied groups.


Eligibility criteria:
inclusion criteria: * indication for total knee arthroplasty * no previous knee surgery * absence of inflammatory arthritis * absence of stiff knee * absence of the following factors: renal failure, liver failure, severe heart failure, respiratory failure, history of thromboembolic events, bleeding disorders, previous strokes exclusion criteria: * none
sublingual photobiomodulation in parkinson's disease

Conditions: Parkinson Disease

Summary: this study evaluates the use of photobiomodulation in the treatment of patients with parkinson's disease. half of participants will receive treatment with low level laser therapy and exercises in combination, while the other half will receive a placebo laser combined with exercises.


Eligibility criteria:
inclusion criteria: * patients with parkinson's disease diagnosed with the criteria of the uk parkinsons' disease society brain bank clinical diagnostic criteria * in the stages i to iii of the disease according to hoehn \& yahr's parkinson's disease staging scale - modified; * individuals of both sexes, * with more than 50 years * who sign the informed consent form exclusion criteria: * patients who present some adverse event during the development of the study, * who have another associated neurodegenerative disease, * have blood dyscrasia, hiv, heart failure, hepatic or renal insufficiency, infections, neoplasias, respiratory disorders, hypophysis and hypothalamus problems. * who fail to understand or perform procedures correctly because of physical and mental limitations.

Keywords: parkinson's disease photobiomodulation inflammation oxidative stress
prospective metabolic indicator study

Conditions: Metabolic Syndrome

Summary: the aim of this study was to assess the impact of a physician-supervised non-surgical medical weight management program on prevalence of metabolic syndrome and to examine the relationship between program retention and levels of key indicators of metabolic syndrome among participants that self-enrolled to the program. a total of 479 overweight or obese participants aged 19 years or older were observed. the revised national cholesterol education program adult treatment panel iii (ncep atp iii) criteria were used to define metabolic syndrome.

each individual self-enrolled to a physician-supervised non-surgical weight management program, hereafter referred to as the program. they received a weight loss intervention as a part of routine medical care in the program. at the end of their first consultation, each individual that met the inclusion criteria and failed to meet the exclusion criteria was asked if he or she would like to join the study. each individual was informed that the study would not change the type or level of care that he or she would receive while enrolled to the program; however, researchers would be studying the effects of their care through additional screenings. individuals who thereafter signed an informed consent form were monitored for changes in health outcomes without change to the program. this study was observational. health outcomes were assessed in individuals that predefined their program status (i.e., enrolled or not enrolled). each participant received routine medical care, and the investigators studied the effects of the intervention. no new intervention or intervention specific to participants only was assigned.

Eligibility criteria:
inclusion criteria: * the patient is at least 18 years of age. * the patient is overweight or obese (bmi≥25 kg/m2). exclusion criteria: - the patient was previously enrolled in the medi-weightloss program

Keywords: metabolic syndrome
the efficacy of hyperthermic intraperitoneal chemotherapy to ovarian cancer patients with homologous recombination repair defect and residual: a prospective cohort study

Conditions: Ovarian Cancer

Summary: ovarian cancer is associated with the highest mortality of all gynecologic cancers. in patients with newly diagnosed advanced ovarian cancer after platinum-containing chemotherapy plus bevacizumab therapy, maintenance therapy with olaparib plus bevacizumab significantly prolongs progression-free survival (pfs) in the intended population and is recommended by guidelines. however, study shows those homologous recombinant repair defect (hrd) but breast cancer susceptibility gene(brca) wild type have limited benefit from maintenance therapy with olaparib plus bevacizumab when surgery is with residual(no-r0). can hyperthermic intraperitoneal chemotherapy(hipec) improve the benefits of first-line maintenance therapy in patients with non-r0 resection, hrd? the cohort study will enroll 310 patients with hrd and no-r0 resection who conduct hipec during primary treatment and then have olaparib plus bevacizumab as maintenance. follow-up period is 30 months. the primary endpoint is pfs.


Eligibility criteria:
inclusion criteria: * age 18-70 years * eastern cooperative oncology group (ecog) score 0-1 * adequate kidney function (blood creatinine 58-96µmol/l) * adequate haematological function (haemoglobin ≥110g/l, leucocytes ≥4.0×109/l, neutrophils ≥2.0×109/l, platelets≥100×109/l) * adequate liver function (serum total bilirubin 3.4-22.2µmol/l, alanine aminotransferase (alt) 7-40u/l, aspartate aminotransferase (ast) 13-35u/l, ast/alt ≤1.5 * surgery with residual * eligible to the maintenance therapy of olaparib plus bevacizumab exclusion criteria: * expected life span ≤8 weeks * complicated with any other known malignancies * patients with dysfunction of swallow and digestion * patients who had received any kind of poly adenosinediphosphate-ribose polymerase（parp）inhibitor * refractory hypertension
image-guided navigation for high dose rate temporary interstitial brachytherapy in the palliative management of previously treated tumors of the spine and pelvis

Conditions: Metastatic or Recurrent Lesions in the Spine; Metastatic or Recurrent Lesions in the Pelvis

Summary: the purpose of this study is to see if using a form of imaging during surgery helps the doctors to guide the placement of radiation catheters more accurately. this method, called "image-guided surgical navigation" may allow the doctors to deliver radiation to the tumor that the patient needs and decrease the amount of radiation delivered to the nearby areas.


Eligibility criteria:
inclusion criteria: * patients must have histologic proof of a malignancy suitable for radiation therapy. * patients must have received prior external beam radiation therapy to the region proposed for hdr brachytherapy treatment; evaluation of doses previously delivered to spinal cord/cauda equine, pelvis, and other critical structures (bowel, kidneys, rectum) will be taken into consideration. * if repeat irradiation would exceed any normal tissue constraint set by mskcc radiation oncology department dose constraint criteria, the patient will potentially be eligible. * if the total prior radiation dose to the cord or pelvis exceeds 100 gy bed equivalent, the patient will be potentially eligible, where a total of 100 bed gy equivalent is determined by the biological equivalent dose (bed) calculation; bed = nd(1 + d/α/β), where n = number of fractions and d = dose per fraction; α/β is the constant for spinal cord late effect and equals 2. \[rades 2005, nieder 2005, sahgal 2012\] * kps ≥ 60 * age ≥ 18 years old exclusion criteria: * patients who may receive therapeutically effective doses via an external beam approach to the lesion of interest as specified by mskcc radiation oncology department dose constraint criteria. * patients with kyphoplasty cement or hardware that would preclude effective catheter placement. * patients with paraspinal extension of disease with visceral involvement. * abnormal complete blood count. any of the following: * platelet count \< 75,000/ml * hb level \< 9gm/dl * wbc \< 3.5/ml * abnormal coagulation profile: inr \> 2.5 and/or ptt \> 80 * patients who are on anticoagulation medication that may not be safely held for the procedure (≥ 5 days for antiplatelet agents and warfarin; ≥ 24 hours for low-molecular weight heparin formulations) will be excluded. * contraindications to general anesthesia

Keywords: radiation therapy hdr brachytherapy ir-192 high dose rate 12-260
zoledronic acid treatment of spontaneous osteonecrosis of the knee

Conditions: Osteonecrosis

Summary: this study will assess the safety and efficacy of zoledronic acid in patients presenting with spontaneous osteonecrosis of the knee.


Eligibility criteria:
inclusion criteria: * adults 40-85 years of age * diagnosis of painful osteonecrosis of the knee within the last month. exclusion criteria: * intravenous (iv) bisphosphonates within the last 2 years. * abnormal thyroid, kidney or liver function. * abnormal blood calcium or alkaline phosphatase levels. other protocol-defined inclusion/exclusion criteria may apply

Keywords: osteonecrosis zoledronic acid knee
exercise and patient education for patients with lateral hip pain

Conditions: Gluteal Tendinitis; Greater Trochanteric Pain Syndrome; Hip and Thigh Injury; Rupture of Hip Abductor Tendon (Disorder)

Summary: this prospective cohort trial will investigate a progressive exercise protocol and patient education for patients with hip abductor tendon pathology. the primary outcome is patient reported pain measured by the revised copenhagen hip and groin outcome score (hagos), that will be conducted at baseline and at a 12 week follow-up.

this study protocol describes an interventional pragmatic prospective single-group cohort study, where the primary endpoint is change in hip pain measured with the revised hagos pain subscale following a 12 week intervention. throughout the 12 weeks, eight physiotherapist-led exercise sessions will take place at horsens regional hospital (hrh). further, at the sessions at hrh patient education will be performed by the supervising physiotherapist. the first supervised sessions will be performed in continuation of the baseline assessment. the patients will be instructed to do the exercises daily at home in the time period between the physiotherapist-led sessions. the primary aim is to investigate changes in patient-reported hip pain based on the subscale "pain" from the revised copenhagen hip and groin outcome score (hagos) from baseline to 12 week follow-up. it is hypothesized that the revised hagos pain score will improve from baseline to 12 week follow-up. secondarily explorative subgroup analyses regarding whether patients with different mri findings, pain profiles, age, sex and body mass index (bmi) respond differently to the intervention, will be performed. all outcomes conducted will be published. that is, patient-reported outcomes, muscle strength, functional capacity and adherence to the exercise protocol. a full study protocol will be published and made available.

Eligibility criteria:
inclusion criteria: * age 18-75 years * mri verified hatp * lateral hip pain duration \> 6 months * ability to read and understand danish. exclusion criteria: * corticosteroid injection in the affected hip joint within the last six weeks prior to the intervention * previous bone-related surgery to the affected hip, * signs of bilateral hatp * x-ray verified hip osteoarthritis * pregnancy

Keywords: exercise patient education lateral hip pain rehabilitation
prismatic correction for improving near visual acuity in patients with maculopathy

Conditions: Visual Acuity

Summary: patients with maculopathy reported in low vision clinic are tested for prismatic glasses for near vision. the pre and post visual acuity was recorded.

diagnosed patient of maculopathy who was visited in low vision clinic are divided in two groups , one is control group (prescribed simple near vision glasses) and other is interventional group(prescribed prismatic glasses). both groups were follow up after one month to check the improvement in near visual acuity

Eligibility criteria:
inclusion criteria: 1. diagnosed patients of maculopathy refer to low vision clinic 2. patients with both genders 3. va from logmar 1.0 to logmar 0.3 exclusion criteria: 1. maculopathy patients with other ocular disease 2. va worsen the logmar 1.0 3. patients with mental illness and other physical lmitations